Life Science Investing Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025
Life Science Investing Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates
Life Science Investing Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November
Life Science Investing Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025
Life Science Investing Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
TomaGold Intercepts 6.68% ZnEq (1.57 g/t AuEq) over 48.05 Metres, including 39.03% ZnEq (9.15 g/t AuEq) over 2.90 Metres at Berrigan Mine and Identifies a Major Hydrothermal Footprint
Apollo Silver Announces Correction to Warrant Terms of $25 Million Strategic Investment by Eric Sprott and Jupiter Asset Management
